N-(1-phenylethyl)-5-(4-methylpiperazino)-2-nitroaniline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(1-phenylethyl)-5-(4-methylpiperazino)-2-nitroaniline
• 英文别名: [5-(4-Methyl-piperazin-1-yl)-2-nitro-phenyl]-(1-phenyl-ethyl)-amine；5-(4-methylpiperazin-1-yl)-2-nitro-N-(1-phenylethyl)aniline
• 化学式: C₁₉H₂₄N₄O₂
• 分子量: 340.425
• InChiKey: RLTJMSYXAHMHKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  64.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-甲基哌嗪 、 N-(1-phenylethyl)-5-chloro-2-nitroaniline 以68%的产率得到N-(1-phenylethyl)-5-(4-methylpiperazino)-2-nitroaniline
  参考文献：
  名称：

  Regular Trends in Nucleophilic Substitutions in 2-Alkylamino-4-chloronitrobenzenes

  摘要：

  研究了位置 2 上的取代基对 2-烷基氨基-4-氯硝基苯在不同性质的 N-亲核物亲核取代中的反应性的影响。

  DOI：

  10.1007/s11178-005-0146-6

文献信息

• Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1676842A1

  公开（公告）日：2006-07-05

  The present invention relates to nitro-substituted phenyl-piperazine compounds of general formula I, a process for their preparation, medicaments comprising said nitro-substituted phenyl-piperazine compounds as well as the use of said nitre-substituted phenyl-piperazine compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT6 receptors.

  本发明涉及一般式I的硝基取代苯基哌嗪化合物，其制备方法，包含所述硝基取代苯基哌嗪化合物的药物，以及利用所述硝基取代苯基哌嗪化合物制备药物，该药物特别适用于预防和/或治疗至少部分通过5-HT6受体介导的疾病或疾病。
• Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1902733A1

  公开（公告）日：2008-03-26

  The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least NMDA-receptor ligand, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种由至少一种具有 5-HT6 受体亲和力的化合物和至少一种 NMDA 受体配体组成的活性物质组合、一种包含所述活性物质组合的药物，以及使用所述活性物质组合制造药物。
• NITRO-SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1851210B1

  公开（公告）日：2011-10-19
• Nitro-Substituted Phenyl-Piperazine Compounds, Their Preparation and Use in Medicaments
  申请人：Aschenbrenner Andrea

  公开号：US20080176854A1

  公开（公告）日：2008-07-24

  The present invention relates to nitro-substituted phenyl-piperazine compounds of general formula I, a process for their preparation, medicaments comprising said nitro-substituted phenyl-piperazine compounds as well as the use of said nitro-substituted phenylpiperazine compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT 6 receptors.
• Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity
  申请人：Buschmann Helmut Heinrich

  公开号：US20100074955A1

  公开（公告）日：2010-03-25

  The present invention relates to an active substance combination comprising at least one compound with 5-HT 6 receptor affinity, and at least NMDA-receptor ligand, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.